Skip to content

Study to assess the effect of Nagabaldya Taila in Patients With Inflammation Of Joints

A comparative Phase II Clinical Study To Evaluate The Efficacy Of Nagbaladya Taila Matra Basti & Nagbaladya Taila Snehapana In Vatarakta

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027898
Enrollment
44
Registered
2020-09-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M10- Gout

Interventions

Intervention1: Nagabaladya Taila: 60 ml per day per rectal route for 7 days Control Intervention1: Nagabaladya Taila: 30 ml once a day before meal with water for 10 days

Sponsors

Arogyashala Rugnalaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed Patients of Vatarakta with symptoms such as sandhishula, sandhidaha, sparshasahatva, sandhishotha, sandhivaivarnya. Patients with raised Serum Uric acid level ( >7 in male & >6 in female). Patient willing for trial & giving written consent. Patient with all socio-economic status.

Exclusion criteria

Exclusion criteria: With known case of major systemic disorders such as IHD, MI, Uncontrolled DM, Uncontrolled Hypertension. Patients other than Gouty Arthritis Basti Anarha. Patient not willing for trial.

Design outcomes

Primary

MeasureTime frame
Reduction of Pain in patient suffering from Vatarakta Improvement in the level of Serum Uric Acid in subject suffering from VataraktaTimepoint: Nagabaladya Tail in Group A for 7 days Nagabaladya Taila in Group B for 10 days

Secondary

MeasureTime frame
Reduction In Inflammation & Redness At Pain SiteTimepoint: Nagabaladya Tail in Group A for 7 days Nagabaladya Taila in Group B for 10 days

Countries

India

Contacts

Public ContactVd Savita A Kulkarni

Ayurved Sewa Sangha Ayurved Mahavidyalaya Nashik

drsavita.k07@gmail.com9423081487

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026